Immix Biopharma Inc

NASDAQ IMMX

Data sourced from iex and EODHD
Download Data

Immix Biopharma Inc Income Statement 2019 - 2023

This table shows the Income Statement for Immix Biopharma Inc going from 2019 until 2023. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Revenue
M 0 -90 0 0 0
Cost of Revenue
M 0 0 0 0 -
Gross Profit
M 0 -90 0 0 -
Operating Expenses
M 16 -81 1 0 -
Selling, General, and Administrative Expenses (SG&A)
M 7 4 1 0 0
Research and Development (R&D) Expenses
M 9 4 0 0 1
Other Operating Expenses
M 0 -90 0 0 -
Costs and Expenses
M 16 8 1 0 -
Operating Income
M -16 -8 -1 0 -1
Interest Expense
M 0 0 0 0 0
Non-operating Income/Expense
M 1 0 -23 -1 0
EBT
M -16 -8 -24 -1 -1
Income Tax Provision
M 0 0 0 0 0
Income after Tax
M -16 -8 -24 -1 -1
Non-Controlling Interest
M - 0 0 0 0
Net Income
M - -8 -24 -1 -1
Shares (Basic, Weighted)
M - - - - -
Shares (Diluted, Weighted)
R 17,341,146.00 13,228,689.00 13,228,689.00 7,773,750.00 8,442,552.00
EBITDA
M -16 -8 -1 0 -1
Depreciation and Amortization
M 0 0 0 0 0
EBIT
M -16 -8 -1 0 -1
Income from Discontinued Operations
M - - - - -
Tax Rate (Effective)
% -0.17 -0.12 -0.02 -1.55 -2.16
Earnings Per Share (EPS), Basic
M - - - - -
Earnings Per Share (EPS), Diluted
M - 0 0 0 0
Gross Profit Margin
% - 100.00 - - -
Operating Income Margin
% - 9.18 - - -
Net Income Margin
% - 9.19 - - -
EBITDA Ratio
% - 9.18 - - -
EBIT Ratio
% - 9.18 - - -
EBT Ratio
% - 9.18 - - -

StockViz Staff

September 19, 2024

Any question? Send us an email